User:Mr. Ibrahem/Dapagliflozin

Dapagliflozin, sold under the brand name Farxiga among others, is a medication used to treat type 2 diabetes. It is also used in heart failure with reduced ejection fraction. In type 1 diabetes, it may be used together with insulin. It is taken by mouth once a day.

Common side effect include urinary tract infections, fungal infections of the groin, increased urination, nausea, and constipation. Other side effects may include low blood sugar, especially when used with other diabetic medications, low blood pressure, Fournier gangrene, allergic reactions, and diabetic ketoacidosis. Use is not recommended in pregnancy or breastfeeding. It is of the gliflozin (SGLT2 inhibitor) class.

Dapagliflozin was approved for medical use in the United States in 2014. It was originally brought to market by AstraZeneca. It is on the World Health Organization's List of Essential Medicines as an alternative to empagliflozin. In the United States it costs about 500 USD per month as of 2020. This amount costs the NHS in the United Kingdom about 40 pounds. In 2017, it was the 259th most commonly prescribed medication in the United States, with more than one million prescriptions.